Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Up 6.46%
As of Monday, November 09, Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 6.46%, which has investors questioning if this is right time to sell.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Tudor Pop
Cynthia McLaughlin
Jenna Brashear
Jenna Brashear
| Share Statistics | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $681.2 | $421.5 | 43% |
|
| Shares Out (Mil) | 445.0 | 46.9 | 87% |
|
| Institutional Ownership | 96.0% | 82.0% | 68% |
|
| Float (Mil) | 219.2 | 49.2 | 75% |
|
| Beta | 1.08 | 0.68 | 64% |
|
| Avg Daily Volume (000s) | 2,408 | 347 | 83% |
|
| Price Change (52-week) |
5.5% | 49.3% | 59% |
|
| Growth | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 15.7% | 6.4% | 74% |
|
| Net Income (5yr) | 3.0% | (1.3%) | 44% |
|
| EPS (5yr) | 23.4% | 15.1% | 74 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.0%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 6 | |
| Current EPS | ($0.054) | ($0.159) | ($0.213) | |
| Month Ago EPS | ($0.036) | ($0.166) | ($0.191) | |
| # Rev Up | 1 | 0 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.036) | ($0.166) | ($0.191) | |
| Year/Year Chg | 74.2% | 14.4% | (23.0%) | |
| Financials | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $39 | $275 | 18% |
|
| Net Income (TTM) (Mil) | ($62) | ($11) | 14% |
|
| EPS (TTM) | ($0.151) | ($0.700) | 34% |
|
| Operating Cash Flow (TTM) (Mil) | ($49) | ($7) | 10% |
|
| Net Cash Flow (TTM) (Mil) | ($35) | $1 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $58 | $6 | 40% |
|
| Enterprise Value (Q1) (Mil) | $669 | $331 | 37% |
|
| Valuation | LXRX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.14 | 2.08 | 78% |
|
| P/E | na | 20.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LXRX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 91.4% | 69.5% | 94% |
|
| Net Margin | (161.8%) | 3.6% | 6% |
|
| ROA | (27.8%) | (23.8%) | 17% |
|
| ROE | (43.9%) | (24.2%) | 16% |
|
| Liabilities to Assets | 32.3% | 31.6% | 23% |
|
| F-Score | 2 | 3 | 7% |
|
Lexicon Pharmaceuticals, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors